Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CRTKVA11-03 TCR-T Cell Injection in Advanced Solid Tumors
NCT07826585Phase 1Active, not recruiting
- Sponsor
- CorreGene
- Start
- Mar 2026
- Primary completion
- Dec 2029
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CRTKVA11-03 in solid tumor, sponsored by CorreGene. Primary endpoints: Dose Limiting Toxicity Incidence Rate at 28 days, Maximum Tolerated Dose at 28 days and 1 more. Started Mar 2026; status: active, not recruiting.
02
Drugs
CRTKVA11-03
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07826585.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07826585.